Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07552779 | A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir | PHASE1 | RECRUITING | 18 | — | — | Apr 13, 2026 | Jul 6, 2026 | Apr 27, 2026 | 1 | Belgium |
Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state
Relative bioavailability of a new oral formulation of ibuzatrelvir compared to the original tablet formulation in the fasted state
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | single dose of ibuzatrelvir original tablet formulation in the fasted state on Day 1 of the treatment period |
| Treatment B | EXPERIMENTAL | single dose of ibuzatrelvir new tablet formulation in the fasted state on Day 1 of the treatment period |
| Treatment C | EXPERIMENTAL | single dose of ibuzatrelvir of the new tablet formulation dispersed in water and given in the fasted state on Day 1 of the treatment period |
| Treatment D | EXPERIMENTAL | single dose of ibuzatrelvir new tablet formulation in the fed state on Day 1 of the treatment period |
| Name | Type | Description |
|---|---|---|
| Ibuzatrelvir co-process API film coated tablet | DRUG | original |
| Ibuzatrelvir filmcoated tablet | DRUG | new |
Inclusion criteria: 1. 18 years of age or older (or the minimum age of consent in accordance with local regulations) at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs. 2. BMI of 16-32 kg/m2; and a tot...